Cystatin C: a step forward in assessing kidney function and cardiovascular risk

Area of Science:

• Nephrology
• Cardiology
• Biomarker Discovery

Background:

• Cardiorenal syndrome highlights the heart-kidney connection, necessitating accurate renal function assessment in cardiac patients.
• Serum creatinine is an unreliable marker for glomerular filtration rate (GFR), particularly when kidney function is unstable.
• Cystatin C (CysC) is an endogenous biomarker with properties making it a superior alternative to creatinine for GFR estimation.

Purpose of the Study:

• To evaluate Cystatin C (CysC) as a more accurate marker of glomerular filtration rate (GFR) compared to creatinine.
• To explore the utility of CysC in assessing renal function in the context of cardiorenal syndrome and acute kidney injury.
• To investigate CysC's role as a prognostic risk marker in cardiovascular disease, including heart failure.

Main Methods:

• Comparison of Cystatin C (CysC) plasma concentrations with creatinine-based estimates of GFR.
• Analysis of CysC's correlation with true GFR, considering factors influencing plasma concentrations.
• Review of studies utilizing CysC for risk stratification in cardiovascular disease and heart failure prognosis.

Main Results:

• Plasma CysC concentrations are less affected by non-GFR factors than creatinine, leading to more accurate GFR correlation.
• Equations for GFR estimation using CysC values facilitate clinical interpretation and application.
• Higher CysC levels consistently predict cardiovascular events, adverse outcomes, and increased mortality in heart failure patients.

Conclusions:

• Cystatin C (CysC) is a valuable and accurate endogenous biomarker for assessing renal function, outperforming creatinine.
• CysC demonstrates significant utility in the clinical assessment of cardiorenal syndrome and acute kidney injury.
• CysC serves as a potent risk marker for cardiovascular events and mortality, crucial for heart failure risk stratification.